A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

About

Brief Summary

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 2

Gender

All

Healthy Volunteers

No

Minimum Age

60 Years

Maximum Age

N/A

Have non-subfoveal (defined as not involving the center point of the fovea) geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an area that can be measured and measures 2.5 millimeter square (mm^2) to 17.5 mm^2 (1- and 7- disc areas respectively), determined by the central reading center (CRC) from screening images of fundus autofluorescence (FAF) and spectral domain optical coherence tomography (SD-OCT)
If GA is multifocal, at least one focal lesion must be greater than or equal to (>=) 1.25 mm^2 (0.5- disc area), as assessed by the CRC
GA can be photographed in its entirety by FAF, using a 30- degree image centered on the fovea, as assessed by the CRC
Fellow eye must be present with a best corrected distance visual acuity (BCVA) of counting fingers or better
Man or woman (according to their reproductive organs and functions assigned by chromosomal complement)

History of transpupillary thermotherapy, photodynamic therapy or external-beam radiation therapy in the region of study eye
Any prior thermal laser in the macular region, regardless of indication
History of retinal detachment (with or without repair)
Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
Any sign of diabetic retinopathy or central serous chorioretinopathy

Contact our clinical trial navigators for opportunities that may be suitable for you

Pre-Screen Now

Call Me Back

855-731-6040

Share:

Study Stats

Protocol No.

22-5125